Pharvaris NV (PHVS)

Currency in USD
34.47
+0.08(+0.23%)
Closed·
33.77-0.70(-2.03%)
·
Advertisement
Earnings results expected in 8 days
PHVS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
34.0535.47
52 wk Range
22.4143.25
Key Statistics
Prev. Close
34.47
Open
34.8
Day's Range
34.05-35.47
52 wk Range
22.41-43.25
Volume
638.33K
Average Volume (3m)
810.3K
1-Year Change
52.3199%
Book Value / Share
4.92
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PHVS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
57.79
Upside
+67.65%
Members' Sentiments
Bearish
Bullish
ProTips
8 analysts have revised their earnings downwards for the upcoming period

Pharvaris NV News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy

Analyst Ratings

14 Buy
0 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 57.79
(+67.65% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BofA Securities
Buy44.00+27.65%-Upgrade23/10/2026
H.C. Wainwright
Buy60.00+74.06%-Maintain06/10/2026
Cantor Fitzgerald
Buy65.00+88.57%65.00Maintain14/09/2026
Guggenheim
Buy44.00+27.65%40.00Maintain10/09/2026
Morgan Stanley
Buy62.00+79.87%46.00Maintain09/09/2026

Earnings

Latest Release
12/08/2026
EPS / Forecast
-0.70 / -0.65
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare PHVS to Peers and Sector

Metrics to compare
PHVS
Peers
Sector
Relationship
P/E Ratio
−12.6x−9.2x−0.2x
PEG Ratio
−0.830.010.00
Price/Book
7.2x5.1x2.6x
Price / LTM Sales
-36.2x2.8x
Upside (Analyst Target)
67.5%98.5%60.9%
Fair Value Upside
Unlock−15.4%9.5%Unlock

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
7.80M11.10%268.71M
Other Institutional Investors
64.68M88.90%2.23B
Public Companies & Retail Investors
0.000.00%0.00
Total
72.48M100.00%2.5B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC9.35%6,565,272226,305
General Atlantic Service Company, L.P.9.33%6,550,757225,805

People Also Watch

34.91
MAZE
+2.11%
138.86
KYMR
+5.41%
50.74
SEPN
+3.87%
38.59
XNCR
+7.94%
15.81
MLYS
+3.13%

FAQ

What Is the Pharvaris NV (NASDAQ: PHVS) Share Price Today?

The Pharvaris NV stock price today is 34.47 USD.

What Stock Exchange Does Pharvaris NV (PHVS) Trade On?

Pharvaris NV is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Pharvaris NV?

The stock symbol (also called a 'ticker') for Pharvaris NV is "PHVS."

What Is the Current Pharvaris NV Market Capitalisation?

As of today, Pharvaris NV (NASDAQ: PHVS) market cap is 2.42B USD.

What Is Pharvaris NV's (PHVS) Earnings Per Share (TTM)?

The Pharvaris NV EPS is currently -2.99 (Trailing Twelve Months).

When Is the Next Pharvaris NV Earnings Date?

Pharvaris NV's next earnings report will be released on 18/11/2026.

Is PHVS a Buy or Sell From a Technical Analyst Perspective?

Based on today's Pharvaris NV moving averages and other technical indicators, the daily buy/sell signal for PHVS stock is Strong Buy.

How Many Times Has Pharvaris NV Stock Split?

Pharvaris NV has split 0 times. (See the PHVS stock split history page for full effective split date and price information.)

How Many Employees Does Pharvaris NV Have?

Pharvaris NV has 148 employees, based on their latest Companies House report.

What is the current trading status of Pharvaris NV (NASDAQ: PHVS)?

As of 10/11/2026, Pharvaris NV (PHVS) is trading at a share price of 34.47 USD, with a previous close of 34.47 USD. The stock has fluctuated within a day range of 34.05 USD to 35.47 USD, while its 52-week range spans from 22.41 USD to 43.25 USD.

What Is Pharvaris NV (PHVS) Price Target According to Analysts?

The average 12-month price target for Pharvaris NV is 57.79 USD, with a high estimate of 79.19519587 USD and a low estimate of 41.10450107 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +67.65% Upside potential.

What Is the PHVS Premarket Price?

PHVS's last pre-market stock price is 33.77 USD. The pre-market share volume is 20.00, and the stock has decreased by -0.70, or -2.03%.

What Is the PHVS After Hours Price?

PHVS's last after hours stock price is 33.91 USD, the stock has decreased by -0.56, or -1.62%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.